Literature DB >> 32640892

High atherogenic index of plasma and cardiovascular risk factors among Ghanaian breast cancer patients.

Emmanuel A Tagoe1,2, Eric Dwamena-Akoto2, Josephine Nsaful3, Anastasia R Aikins1, Joe-Nat Clegg-Lamptey3, Osbourne Quaye1.   

Abstract

Comorbidities impact negatively on breast cancer prognosis, especially in developing countries where cases are usually presented to clinics at advanced stages. This study aimed to determine the atherogenic index of plasma (AIP) and cardiovascular risk factors among Ghanaian women diagnosed with breast cancer. A total of 52 breast cancer patients were age-matched with 52 healthy controls. Sociodemographics of participants were obtained using a well-structured questionnaire. Pathological data of patients were obtained from medical records, and all clinical and anthropometric measurements were done using standard instruments. Lipid profile was determined from serum using enzymatic assays, and cardiovascular risk factors were calculated from estimated lipid parameters. Blood pressure, AIP, total cholesterol (T. chol), triglyceride (TG), and low-density lipoprotein cholesterol (LDL-c) were significantly elevated (P < 0.05) in the breast cancer patients compared to the controls, but the reverse was observed for high-density lipoprotein cholesterol (HDL-c) (P < 0.01). Obesity (odds ratio [OR] = 2.51, P = 0.015), hypertension (OR = 4.04, P < 0.001), AIP (OR = 10.44, P < 0.001), and dyslipidemia (P < 0.01) were significantly associated with breast cancer. AIP correlated positively with age (r = 0.244, P < 0.05), body mass index (r = 0.225, P < 0.05), blood pressure (P < 0.01), T. chol (r =0.418, P< 0.01), and TG (r = 0.880, P < 0.01), but inversely correlated with HDL-c (r = -0.460, P < 0.01). A greater proportion (88%) of the patients presented with advanced breast cancer. AIP and cardiovascular risk factors were high in the breast cancer patients. Considering that AIP and cardiovascular disease risk factors are of interest in breast cancer patients, further studies are needed to understand the effect of AIP and cardiovascular risk factors on breast cancer outcomes.

Entities:  

Keywords:  Breast cancer; atherogenic index of plasma; cardiovascular risk; dyslipidemia; hypertension; obesity

Year:  2020        PMID: 32640892      PMCID: PMC7802380          DOI: 10.1177/1535370220940992

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  41 in total

1.  Demographic changes in breast cancer incidence, stage at diagnosis and age associated with population-based mammographic screening.

Authors:  Francys C Verdial; Ruth Etzioni; Catherine Duggan; Benjamin O Anderson
Journal:  J Surg Oncol       Date:  2017-02-14       Impact factor: 3.454

2.  Nutrition and physical activity cancer prevention guidelines, cancer risk, and mortality in the women's health initiative.

Authors:  Cynthia A Thomson; Marjorie L McCullough; Betsy C Wertheim; Rowan T Chlebowski; Maria Elena Martinez; Marcia L Stefanick; Thomas E Rohan; Joann E Manson; Hilary A Tindle; Judith Ockene; Mara Z Vitolins; Jean Wactawski-Wende; Gloria E Sarto; Dorothy S Lane; Marian L Neuhouser
Journal:  Cancer Prev Res (Phila)       Date:  2014-01

3.  Haptoglobin phenotypes with weak antioxidant capacity increase risk factors of cardiovascular disease in Ghanaian HIV-infected patients on highly active antiretroviral therapy.

Authors:  Emmanuel Ayitey Tagoe; Ishmael Nii Ayibontey Tagoe; Joshua Agbemefa Kuleape; Peter Puplampu; Seth Amanquah; Henry Asare-Anane; Osbourne Quaye
Journal:  Trop Med Int Health       Date:  2019-03-21       Impact factor: 2.622

4.  Healthy lifestyle impact on breast cancer-specific and all-cause mortality.

Authors:  Adaline E Heitz; Richard N Baumgartner; Kathy B Baumgartner; Stephanie D Boone
Journal:  Breast Cancer Res Treat       Date:  2017-08-31       Impact factor: 4.872

Review 5.  Obesity and obesity-initiated metabolic syndrome: mechanistic links to chronic kidney disease.

Authors:  Ihab M Wahba; Robert H Mak
Journal:  Clin J Am Soc Nephrol       Date:  2007-03-14       Impact factor: 8.237

6.  Profiles of lipids, blood pressure and weight changes among premenopausal Chinese breast cancer patients after adjuvant chemotherapy.

Authors:  Winnie Yeo; Frankie K F Mo; Elizabeth Pang; Joyce J S Suen; Jane Koh; Herbert H F Loong; Christopher C H Yip; Rita Y W Ng; Claudia H W Yip; Nelson L S Tang; Giok S Liem
Journal:  BMC Womens Health       Date:  2017-07-27       Impact factor: 2.809

7.  Understanding the Relationship between Atherogenic Index of Plasma and Cardiovascular Disease Risk Factors among Staff of an University in Malaysia.

Authors:  Myat Su Bo; Whye Lian Cheah; Soe Lwin; Tin Moe Nwe; Than Than Win; Myint Aung
Journal:  J Nutr Metab       Date:  2018-07-04

Review 8.  Updating the role of obesity and cholesterol in breast cancer.

Authors:  Laura Garcia-Estevez; Gema Moreno-Bueno
Journal:  Breast Cancer Res       Date:  2019-03-01       Impact factor: 6.466

9.  The atherogenic index of plasma is a strong and independent predictor for coronary artery disease in the Chinese Han population.

Authors:  Gaojun Cai; Ganwei Shi; Sheliang Xue; Wei Lu
Journal:  Medicine (Baltimore)       Date:  2017-09       Impact factor: 1.889

10.  Obesity and inflammation: the linking mechanism and the complications.

Authors:  Mohammed S Ellulu; Ismail Patimah; Huzwah Khaza'ai; Asmah Rahmat; Yehia Abed
Journal:  Arch Med Sci       Date:  2016-03-31       Impact factor: 3.318

View more
  2 in total

1.  Combining contrast-enhanced ultrasound and blood cell analysis to improve diagnostic accuracy of plasma cell mastitis.

Authors:  Yan Zheng; Lin Wang; Xiu Han; Lin Shen; Chen Ling; Zhongping Qian; Lin Zhu; Fenglin Dong; Qingzhen Han
Journal:  Exp Biol Med (Maywood)       Date:  2021-10-09

2.  Analysis of risk factors associated with breast cancer in women: a systematic review and meta-analysis.

Authors:  Hulin Liu; Suling Shi; Jinnan Gao; Jun Guo; Min Li; Linying Wang
Journal:  Transl Cancer Res       Date:  2022-05       Impact factor: 0.496

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.